Get the Stockscreener App
98.66
4.92%
-5.10
After Hours:
98.20
-0.46
-0.47%
Biontech Se Adr stock is traded at $98.66, with a volume of 1.10M.
It is down -4.92% in the last 24 hours and up +5.33% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
See More
Previous Close:
$103.76
Open:
$100.24
24h Volume:
1.10M
Relative Volume:
0.93
Market Cap:
$24.78B
Revenue:
$3.26B
Net Income/Loss:
$-1.45B
P/E Ratio:
-16.80
EPS:
-5.871
Net Cash Flow:
$1.18B
1W Performance:
-3.22%
1M Performance:
+5.33%
6M Performance:
-2.80%
1Y Performance:
-3.90%
1-Day Range:
$98.18
$101.33
1-Week Range:
$98.18
$105.46
52-Week Range:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
98.66 | 26.06B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
528.90 | 138.42B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
810.31 | 85.22B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,007.07 | 64.63B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
140.33 | 58.11B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.32 | 45.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-16-26 | Upgrade | Goldman | Neutral → Buy |
| Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
| May-29-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Why Pfizer Stock Was so Healthy in August - The Motley Fool
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Why is BioNTech stock sliding today? - Investing.com
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Eastern Progress
BioNTech's September Test: Can Oncology Data Outweigh a Shrinking COVID Franchise? () - aktiencheck.de
BioNTech SEADR (BNTX) Fundamental & Financial Data - Stocktwits
BioNTech's Seoul Moment: Why One Halted Trial Hasn't Derailed the Oncology Narrative () - aktiencheck.de
BioNTech's September Crossroads: Seoul Data Readouts and Factory Decisions Will Test the Post-Trial Narrative - aktiencheck.de
BioNTech's Two-Front Battle: Legal Overhang in Europe Meets a Pivotal September for Oncology Data - aktiencheck.de
BNTX stock reacts to halted cancer trial and lower 2026 guidance - AD HOC NEWS
Zacks Investment ResearchGlobes - Globes - Israel Business News
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down - Eastern Progress
BioNTech's Leadership Exodus Looms as Vaccine Franchise Holds While Oncology Ambitions Take a Hit - aktiencheck.de
BioNTech's Split-Screen Week: A Trial Halted, a Vaccine Approved, and a Pipeline Under the Microscope - aktiencheck.de
Why is BioNTech stock down 7.8% today? - Traders Union
BioNTech stock tumbles 10% on cancer trial termination - Investing.com
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine - Barchart.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
FDA approves Pfizer-BioNTech COVID vaccine targeting XFG variant - Investing.com
global market • stocks • Vienna Stock Exchange - Wiener Börse
Should You Buy Moderna Stock Following Its Cancer Breakthrough? - tradingview.com
BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing - Barchart.com
Market Wrap: Stocks Fall as Industrials and Utilities Decline - Morningstar
BioNTech’s New HIV RNA Vaccine Trial: What Investors Should Watch Now - TipRanks
BioNTech jumps $5.1 billion in premarket; analyst target now just 8% higher - TechStock²
Merck Raises the Stakes for Pfizer's Cancer Vaccine AmbitionsModerna (NASDAQ:MRNA), Merck & Co (NYSE:M - Benzinga
Is Cancer the Next Breakthrough for Moderna After COVID-19? - TradingView
Moderna ascends more than 175% from cancer vaccine breakthrough - Mugglehead Investment Magazine
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 - Barchart.com
BioNTech SE Stock Jumps As Traders Bet On Post-COVID Pivot - StocksToTrade
European ADRs Rose In US Trading, Led By BioNTech - Finimize
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday - Benzinga
BioNTech Up Over 21%, On Track for Largest Percent Increase Since May 2020 -- Data Talk - Moomoo
BioNTech’s rally on Moderna trial win likely to fade, Leerink says - Seeking Alpha
BNTX Stock Quote Price and Forecast - CNN
U.S. Listings For German Scale-ups | Part 2 - orrick.com
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BIONTECH SE BIONTECH SE ADR (0A3M.L) Q1 FY2026 earnings call transcript - Yahoo Finance
BioNTech SE (BNTX) stock price, news, quote and history - Yahoo Finance Australia
BioNTech (BNTX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock - TradingView
Bank of America Corp DE Raises Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Double Whammy: A CEO Transition Lands in the Middle of a Guidance Cut () - aktiencheck.de
Assenagon Asset Management S.A. Makes New $39.38 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Second Quarter Puts a Founder's Exit and a Shrinking COVID Franchise in Sharp Relief - aktiencheck.de
Bank of New York Mellon Corp Trims Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pfizer and BioNTech Advance Next‑Season Pediatric COVID‑19 Booster Strategy With New Phase 3 Update - TipRanks
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.27%
18.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):